Proton pump inhibitors omeprazole and lansoprazole contain chiral sulfur atom and they are administered as a racemate, i.e. equimolar mixture of S- and R-enantiomers. The enantiopure drugs esomeprazole and dexlansoprazole have been developed and introduced to clinical practice due to their improved clinical and therapeutic properties. Since omeprazole and lansoprazole are activators of aryl hydrocarbon receptor (AhR) and inducers of CYP1A genes, we examined their enantiospecific effects on AhR-CYP1A pathway in human cancer cells and primary human hepatocytes. We performed gene reporter assays for transcriptional activity of AhR, RT-PCR analyses for CYP1A1/2 mRNAs, western blots for CYP1A1/2 proteins and EROD assay for CYP1A1/2 catalytic activity. Lansoprazole and omeprazole enantiomers displayed differential effects on AhR-CYP1A1/2 pathway. In general, S-enantiomers were stronger activators of AhR and inducers of CYP1A genes as compared to R-enantiomers in lower concentrations, i.e. 1-10 µM for lansoprazole and 10-100 µM for omeprazole. In contrast, R-enantiomers were stronger AhR activators and CYP1A inducers than S-enantiomers in higher concentrations, i.e. 100 µM for lansoprazole and 250 µM for omeprazole. In conclusion, we provide the first evidence of enantiospecific effects of omeprazole and lansoprazole on AhR signaling pathway.

Department of Cell Biology and Genetics Faculty of Science Palacky University Olomouc Czech Republic

See more in PubMed

Sachs G, Shin JM, Besancon M, Prinz C (1993) The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 7 Suppl 14–12 discussion 29–31. PubMed

Shin JM, Sachs G (2004) Differences in binding properties of two proton pump inhibitors on the gastric H+,K+−ATPase in vivo. Biochem Pharmacol 68: 2117–2127. PubMed

Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B (1986) The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 29: 1327–1329. PubMed

Kohl B, Sturm E, Senn-Bilfinger J, Simon WA, Kruger U, et al. (1992) (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate. J Med Chem 35: 1049–1057. PubMed

Andersson T, Weidolf L (2008) Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28: 263–279. PubMed

Andersson T, Rohss K, Bredberg E, Hassan-Alin M (2001) Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 15: 1563–1569. PubMed

Kendall MJ (2003) Review article: esomeprazole—the first proton pump inhibitor to be developed as an isomer. Aliment Pharmacol Ther 17 Suppl 11–4. PubMed

Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, et al. (1996) Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 13: 611–615. PubMed

Metz DC, Vakily M, Dixit T, Mulford D (2009) Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 29: 928–937. PubMed

Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31: 9–28. PubMed

Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, et al. (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47: 410–418. PubMed

Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, et al. (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28: 966–972. PubMed

Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, et al. (1994) Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 269: 384–392. PubMed

Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC (1999) Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol 18: 95–105. PubMed

Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U (2003) Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica 33: 107–118. PubMed

Lusska A, Wu L, Whitlock JP Jr (1992) Superinduction of CYP1A1 transcription by cycloheximide. Role of the DNA binding site for the liganded Ah receptor. J Biol Chem 267: 15146–15151. PubMed

Neuhold LA, Shirayoshi Y, Ozato K, Jones JE, Nebert DW (1989) Regulation of mouse CYP1A1 gene expression by dioxin: requirement of two cis-acting elements during induction. Mol Cell Biol 9: 2378–2386. PubMed PMC

Lesca P, Peryt B, Larrieu G, Alvinerie M, Galtier P, et al. (1995) Evidence for the ligand-independent activation of the AH receptor. Biochem Biophys Res Commun 209: 474–482. PubMed

Vrzal R, Frauenstein K, Proksch P, Abel J, Dvorak Z, et al. (2013) Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells. PLoS One 8: e74917. PubMed PMC

Vrzal R, Stejskalova L, Monostory K, Maurel P, Bachleda P, et al. (2009) Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact 179: 288–296. PubMed

Novotna A, Pavek P, Dvorak Z (2011) Novel stably transfected gene reporter human hepatoma cell line for assessment of aryl hydrocarbon receptor transcriptional activity: construction and characterization. Environ Sci Technol 45: 10133–10139. PubMed

Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, et al. (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31: 1227–1234. PubMed

Miura M (2006) Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 126: 395–402. PubMed

Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes

Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells

Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis